Active surveillance for the management of prostate cancer in a contemporary cohort

Marc Dall'Era, Badrinath R. Konety, Janet E. Cowan, Katsuto Shinohara, Frank Stauf, Matthew R. Cooperberg, Maxwell V. Meng, Christopher J. Kane, Nanette Perez, Viraj A. Master, Peter R. Carroll

Research output: Contribution to journalArticle

319 Citations (Scopus)

Abstract

BACKGROUND. Active surveillance followed by selective treatment for men who have evidence of disease progression may be an option for select patients with early-stage prostate cancer. In this article, the authors report their experience in a contemporary cohort of men with prostate cancer who were managed with active surveillance. METHODS. All men who were managed initially with active surveillance were identified through the authors' institutional database. Selection criteria for active surveillance included: prostate-specific antigen (PSA) <10 ng/mL, biopsy Gleason sum ≤6 with no pattern 4 or 5, cancer involvement of <33% of biopsy cores, and clinical stage T1/T2a tumor. Patients were followed with PSA measurements and digital rectal examination every 3 to 6 months and with transrectal ultrasound at 6- to 12-month intervals. Beginning in 2003, patients also underwent repeat prostate biopsy at 12 to 24 months. The primary outcome measured was active treatment. Evidence of disease progression, defined as an increase in rebiopsy Gleason sum or significant PSA velocity changes (>0.75 ng/mL per year), was a secondary outcome. Chi-square and log-rank tests were used to compare groups. The association between clinical characteristics and receipt of active treatment was analyzed by using Cox proportional hazards regression. RESULTS. Three hundred twenty-one men (mean age [±standard deviation]: 63.4 ± 8.5 years) selected active surveillance as their initial management. The overall median follow-up was 3.6 years (range, 1-17 years). The initial mean PSA level was 6.5 ± 3.9 ng/mL. One hundred twenty men (37%) met at least 1 criterion for progression. Overall, 38% of men had higher grade on repeat biopsy, and 26% of men had a PSA velocity >0.75 ng/mL per year. Seventy-eight men (24%) received secondary treatment at a median 3 years (range, 1-17 years) after diagnosis. Approximately 13% of patients with no disease progression elected to obtain treatment. PSA density at diagnosis and rise in Gleason score on repeat biopsy were associated significantly with receipt of secondary treatment. The disease-specific survival rate was 100%. CONCLUSIONS. Selected individuals with early-stage prostate cancer may be candidates for active surveillance. Specific criteria can be and need to be developed to select the most appropriate individuals for this form of management and to monitor disease progression. A small attrition rate can be expected because of men who are unable or unwilling to tolerate surveillance.

Original languageEnglish (US)
Pages (from-to)2664-2670
Number of pages7
JournalCancer
Volume112
Issue number12
DOIs
StatePublished - Jun 15 2008

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Disease Progression
Biopsy
Therapeutics
Neoplasm Grading
Patient Selection
Survival Rate
Databases

Keywords

  • Active surveillance
  • Criteria
  • Prostate cancer
  • Watchful waiting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dall'Era, M., Konety, B. R., Cowan, J. E., Shinohara, K., Stauf, F., Cooperberg, M. R., ... Carroll, P. R. (2008). Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer, 112(12), 2664-2670. https://doi.org/10.1002/cncr.23502

Active surveillance for the management of prostate cancer in a contemporary cohort. / Dall'Era, Marc; Konety, Badrinath R.; Cowan, Janet E.; Shinohara, Katsuto; Stauf, Frank; Cooperberg, Matthew R.; Meng, Maxwell V.; Kane, Christopher J.; Perez, Nanette; Master, Viraj A.; Carroll, Peter R.

In: Cancer, Vol. 112, No. 12, 15.06.2008, p. 2664-2670.

Research output: Contribution to journalArticle

Dall'Era, M, Konety, BR, Cowan, JE, Shinohara, K, Stauf, F, Cooperberg, MR, Meng, MV, Kane, CJ, Perez, N, Master, VA & Carroll, PR 2008, 'Active surveillance for the management of prostate cancer in a contemporary cohort', Cancer, vol. 112, no. 12, pp. 2664-2670. https://doi.org/10.1002/cncr.23502
Dall'Era M, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008 Jun 15;112(12):2664-2670. https://doi.org/10.1002/cncr.23502
Dall'Era, Marc ; Konety, Badrinath R. ; Cowan, Janet E. ; Shinohara, Katsuto ; Stauf, Frank ; Cooperberg, Matthew R. ; Meng, Maxwell V. ; Kane, Christopher J. ; Perez, Nanette ; Master, Viraj A. ; Carroll, Peter R. / Active surveillance for the management of prostate cancer in a contemporary cohort. In: Cancer. 2008 ; Vol. 112, No. 12. pp. 2664-2670.
@article{332eeaaf44944a3693a1bfd2cc5f5a4d,
title = "Active surveillance for the management of prostate cancer in a contemporary cohort",
abstract = "BACKGROUND. Active surveillance followed by selective treatment for men who have evidence of disease progression may be an option for select patients with early-stage prostate cancer. In this article, the authors report their experience in a contemporary cohort of men with prostate cancer who were managed with active surveillance. METHODS. All men who were managed initially with active surveillance were identified through the authors' institutional database. Selection criteria for active surveillance included: prostate-specific antigen (PSA) <10 ng/mL, biopsy Gleason sum ≤6 with no pattern 4 or 5, cancer involvement of <33{\%} of biopsy cores, and clinical stage T1/T2a tumor. Patients were followed with PSA measurements and digital rectal examination every 3 to 6 months and with transrectal ultrasound at 6- to 12-month intervals. Beginning in 2003, patients also underwent repeat prostate biopsy at 12 to 24 months. The primary outcome measured was active treatment. Evidence of disease progression, defined as an increase in rebiopsy Gleason sum or significant PSA velocity changes (>0.75 ng/mL per year), was a secondary outcome. Chi-square and log-rank tests were used to compare groups. The association between clinical characteristics and receipt of active treatment was analyzed by using Cox proportional hazards regression. RESULTS. Three hundred twenty-one men (mean age [±standard deviation]: 63.4 ± 8.5 years) selected active surveillance as their initial management. The overall median follow-up was 3.6 years (range, 1-17 years). The initial mean PSA level was 6.5 ± 3.9 ng/mL. One hundred twenty men (37{\%}) met at least 1 criterion for progression. Overall, 38{\%} of men had higher grade on repeat biopsy, and 26{\%} of men had a PSA velocity >0.75 ng/mL per year. Seventy-eight men (24{\%}) received secondary treatment at a median 3 years (range, 1-17 years) after diagnosis. Approximately 13{\%} of patients with no disease progression elected to obtain treatment. PSA density at diagnosis and rise in Gleason score on repeat biopsy were associated significantly with receipt of secondary treatment. The disease-specific survival rate was 100{\%}. CONCLUSIONS. Selected individuals with early-stage prostate cancer may be candidates for active surveillance. Specific criteria can be and need to be developed to select the most appropriate individuals for this form of management and to monitor disease progression. A small attrition rate can be expected because of men who are unable or unwilling to tolerate surveillance.",
keywords = "Active surveillance, Criteria, Prostate cancer, Watchful waiting",
author = "Marc Dall'Era and Konety, {Badrinath R.} and Cowan, {Janet E.} and Katsuto Shinohara and Frank Stauf and Cooperberg, {Matthew R.} and Meng, {Maxwell V.} and Kane, {Christopher J.} and Nanette Perez and Master, {Viraj A.} and Carroll, {Peter R.}",
year = "2008",
month = "6",
day = "15",
doi = "10.1002/cncr.23502",
language = "English (US)",
volume = "112",
pages = "2664--2670",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Active surveillance for the management of prostate cancer in a contemporary cohort

AU - Dall'Era, Marc

AU - Konety, Badrinath R.

AU - Cowan, Janet E.

AU - Shinohara, Katsuto

AU - Stauf, Frank

AU - Cooperberg, Matthew R.

AU - Meng, Maxwell V.

AU - Kane, Christopher J.

AU - Perez, Nanette

AU - Master, Viraj A.

AU - Carroll, Peter R.

PY - 2008/6/15

Y1 - 2008/6/15

N2 - BACKGROUND. Active surveillance followed by selective treatment for men who have evidence of disease progression may be an option for select patients with early-stage prostate cancer. In this article, the authors report their experience in a contemporary cohort of men with prostate cancer who were managed with active surveillance. METHODS. All men who were managed initially with active surveillance were identified through the authors' institutional database. Selection criteria for active surveillance included: prostate-specific antigen (PSA) <10 ng/mL, biopsy Gleason sum ≤6 with no pattern 4 or 5, cancer involvement of <33% of biopsy cores, and clinical stage T1/T2a tumor. Patients were followed with PSA measurements and digital rectal examination every 3 to 6 months and with transrectal ultrasound at 6- to 12-month intervals. Beginning in 2003, patients also underwent repeat prostate biopsy at 12 to 24 months. The primary outcome measured was active treatment. Evidence of disease progression, defined as an increase in rebiopsy Gleason sum or significant PSA velocity changes (>0.75 ng/mL per year), was a secondary outcome. Chi-square and log-rank tests were used to compare groups. The association between clinical characteristics and receipt of active treatment was analyzed by using Cox proportional hazards regression. RESULTS. Three hundred twenty-one men (mean age [±standard deviation]: 63.4 ± 8.5 years) selected active surveillance as their initial management. The overall median follow-up was 3.6 years (range, 1-17 years). The initial mean PSA level was 6.5 ± 3.9 ng/mL. One hundred twenty men (37%) met at least 1 criterion for progression. Overall, 38% of men had higher grade on repeat biopsy, and 26% of men had a PSA velocity >0.75 ng/mL per year. Seventy-eight men (24%) received secondary treatment at a median 3 years (range, 1-17 years) after diagnosis. Approximately 13% of patients with no disease progression elected to obtain treatment. PSA density at diagnosis and rise in Gleason score on repeat biopsy were associated significantly with receipt of secondary treatment. The disease-specific survival rate was 100%. CONCLUSIONS. Selected individuals with early-stage prostate cancer may be candidates for active surveillance. Specific criteria can be and need to be developed to select the most appropriate individuals for this form of management and to monitor disease progression. A small attrition rate can be expected because of men who are unable or unwilling to tolerate surveillance.

AB - BACKGROUND. Active surveillance followed by selective treatment for men who have evidence of disease progression may be an option for select patients with early-stage prostate cancer. In this article, the authors report their experience in a contemporary cohort of men with prostate cancer who were managed with active surveillance. METHODS. All men who were managed initially with active surveillance were identified through the authors' institutional database. Selection criteria for active surveillance included: prostate-specific antigen (PSA) <10 ng/mL, biopsy Gleason sum ≤6 with no pattern 4 or 5, cancer involvement of <33% of biopsy cores, and clinical stage T1/T2a tumor. Patients were followed with PSA measurements and digital rectal examination every 3 to 6 months and with transrectal ultrasound at 6- to 12-month intervals. Beginning in 2003, patients also underwent repeat prostate biopsy at 12 to 24 months. The primary outcome measured was active treatment. Evidence of disease progression, defined as an increase in rebiopsy Gleason sum or significant PSA velocity changes (>0.75 ng/mL per year), was a secondary outcome. Chi-square and log-rank tests were used to compare groups. The association between clinical characteristics and receipt of active treatment was analyzed by using Cox proportional hazards regression. RESULTS. Three hundred twenty-one men (mean age [±standard deviation]: 63.4 ± 8.5 years) selected active surveillance as their initial management. The overall median follow-up was 3.6 years (range, 1-17 years). The initial mean PSA level was 6.5 ± 3.9 ng/mL. One hundred twenty men (37%) met at least 1 criterion for progression. Overall, 38% of men had higher grade on repeat biopsy, and 26% of men had a PSA velocity >0.75 ng/mL per year. Seventy-eight men (24%) received secondary treatment at a median 3 years (range, 1-17 years) after diagnosis. Approximately 13% of patients with no disease progression elected to obtain treatment. PSA density at diagnosis and rise in Gleason score on repeat biopsy were associated significantly with receipt of secondary treatment. The disease-specific survival rate was 100%. CONCLUSIONS. Selected individuals with early-stage prostate cancer may be candidates for active surveillance. Specific criteria can be and need to be developed to select the most appropriate individuals for this form of management and to monitor disease progression. A small attrition rate can be expected because of men who are unable or unwilling to tolerate surveillance.

KW - Active surveillance

KW - Criteria

KW - Prostate cancer

KW - Watchful waiting

UR - http://www.scopus.com/inward/record.url?scp=46049120853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46049120853&partnerID=8YFLogxK

U2 - 10.1002/cncr.23502

DO - 10.1002/cncr.23502

M3 - Article

C2 - 18433013

AN - SCOPUS:46049120853

VL - 112

SP - 2664

EP - 2670

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -